search

Cerus Corporation (CERS)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Cerus (NASDAQ:CERS) Stock Rating Upgraded by Wall Street Zen
Nov 7, 2026

Cerus (NASDAQ:CERS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen has upgraded Cerus (NASDAQ:CERS) from a "hold" to a "buy" rating, despite mixed views from other analysts, which result in a consensus "hold" rating with an average price target of $5.25. The stock opened at $2.02, with a 52-week range of $1.42–$3.47 and a market capitalization of approximately $407 million. Institutional investors and hedge funds hold 78.37% of Cerus shares, while an insider recently sold 30,000 shares.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Neutral
Cerus: Q3 Earnings Snapshot
Nov 2, 2026

Cerus: Q3 Earnings Snapshot

Cerus Corp. (CERS) reported a third-quarter loss of $550,000, resulting in a per-share loss of less than 1 cent. The biomedical products company generated $57.7 million in revenue for the period and projects full-year revenue to be between $229 million and $231 million.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Somewhat-Bearish